{"id":"W2903493423","doi":"10.1016/s0140-6736(18)31999-8","title":"Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study","year":2018,"lang":"en","type":"article","venue":"The Lancet","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":1697,"is_retracted":false,"has_abstract":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Merck Sharp and Dohme; National Institute for Health and Care Research","keywords":"Cetuximab; Medicine; Docetaxel; Pembrolizumab; Oncology; Open label; Internal medicine; Head and neck; Methotrexate; Head and neck squamous-cell carcinoma; Head and neck cancer; Phases of clinical research; Chemotherapy; Randomized controlled trial; Surgery; Radiation therapy; Cancer; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null}